cisplatin
Trade name: platinol
Approved
Dec 19, 1978
There is no available sources on the medical use of platinum iodide. The salt is insoluble. — NCATS
Clinical trial activity
3,539 trials · 1,240 clinical orgs · 13 marketing orgs
Earliest trial started Apr 1, 1988 (NCT00002461)
Timeline
1970s
- Dec 19, 1978
Bristol-Myers — Earliest FDA Approval
- Dec 19, 1978
Hq Speciality Pharma — NDA Secondary Org
- Dec 19, 1978
Bristol-Myers — NDA Organization
2000s
- May 16, 2000
Pharmachemie Bv — Marketing Organization
- May 16, 2000
Teva — Marketing Organization
- Nov 7, 2000
West-Ward Pharmaceutical — Marketing Organization
- Nov 7, 2000
Hikma — Marketing Organization
- Nov 14, 2000
Bedford Pharmaceuticals — Marketing Organization
2010s
- Apr 18, 2012
Mylan — Marketing Organization
- Apr 18, 2012
PHARMOBEDIENT — Marketing Organization
- Aug 18, 2015
Accord Research — Marketing Organization
- Mar 17, 2017
Gland Pharma Ltd — Marketing Organization
2020s
- May 10, 2024
Qilu Pharmaceutical Co., Ltd. — Marketing Organization
Indications
Approved for
Studied for
- Abdominal Neoplasms · Phase 2
- Acquired Immunodeficiency Syndrome · Phase 2
- Acute Kidney Injury · Phase 2
- Adenocarcinoma · Phase 4
- Adenocarcinoma of Lung · Phase 4
- Adenoma, Islet Cell · Phase 2
- Adrenal Gland Neoplasms · Phase 3
- Adrenocortical Carcinoma · Phase 3
- Aggression · Phase 3
- Albumin-Bound Paclitaxel · Phase 1/Phase 2
- Alzheimer Disease · Phase 1
- Androgens · Phase 1
- Anemia · Phase 4
- Angiogenesis Modulating Agents · Phase 2
- Anterior Cruciate Ligament Injuries · Phase 2
- Antineoplastic Agents · Phase 2
- Anus Neoplasms · Phase 3
- Anxiety Disorders · Phase 2
- Appendiceal Neoplasms · Phase 1
- Ascites · Phase 2
- Astrocytoma · Phase 1
- Basal Cell Carcinoma · Phase 1/Phase 2
- Bevacizumab · Phase 2
- Bile Duct Neoplasms · Phase 3
- Biliary Tract Neoplasms · Phase 4
- Biomarkers · Phase 2
- Bone Marrow Diseases · Phase 2
- Bone Neoplasms · Phase 1/Phase 2
- Brain Neoplasms · Phase 3
- BRCA1 Protein · Phase 3
- Breast Neoplasms · Phase 4
- Breast Neoplasms, Male · Phase 1
- Brenner Tumor · Phase 1
- Bronchial Diseases · Phase 3
- Bronchial Neoplasms · Phase 2
- Burkitt Lymphoma · Phase 1/Phase 2
- Cancer Vaccines · Phase 2
- Carboplatin · Phase 3
- Carcinoma · Phase 3
- Carcinoma, Adenoid Cystic · Phase 2
- Carcinoma, Adenosquamous · Phase 2
- Carcinoma, Bronchogenic · Phase 3
- Carcinoma, Endometrioid · Phase 1
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Mucoepidermoid · Phase 2
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 4
- Carcinoma, Ovarian Epithelial · Phase 3
- Carcinoma, Pancreatic Ductal · Phase 1
- Carcinoma, Renal Cell · Phase 3
- Carcinoma, Small Cell · Phase 3
- Carcinoma, Squamous Cell · Phase 4
- Carcinoma, Transitional Cell · Phase 3
- Carcinoma, Verrucous · Phase 3
- Cardiotoxicity · Phase 3
- Central Nervous System Neoplasms · Phase 3
- Chemical and Drug Induced Liver Injury · Phase 4
- Chemoradiotherapy · Phase 3
- Chemotherapy, Adjuvant · Phase 3
- Child · Phase 2
- Cholangiocarcinoma · Phase 3
- Chondrosarcoma · Phase 1/Phase 2
- Choriocarcinoma · Phase 3
- Choroid Plexus Neoplasms · Phase 3
- Circulating Tumor DNA · Phase 2
- Cisplatin · Phase 3
- Clonal Hematopoiesis · Phase 2
- Cognition Disorders · Phase 3
- Cognitive Dysfunction · Phase 1
- Colitis, Ulcerative · Phase 1/Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 3
- Cyclophosphamide · Phase 2
- Cysts · Phase 3
- Cytoreduction Surgical Procedures · Phase 2
- Death · Phase 2
- Dentin Sensitivity · Phase 1
- Depression · Phase 2
- Desmoplastic Small Round Cell Tumor · Phase 1
- Dexamethasone · Phase 2
- Digestive System Diseases · Phase 1/Phase 2
- Digestive System Neoplasms · Phase 2
- Disease-Free Survival · Phase 2/Phase 3
- Disease Progression · Phase 2
- Doxorubicin · Phase 3
- Drug Evaluation · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Drugs, Investigational · Phase 3
- Drug Therapy · Phase 3
- Drug Therapy, Combination · Phase 1/Phase 2
- Endocrine Gland Neoplasms · Phase 1/Phase 2
- Endocrine System Diseases · Phase 1/Phase 2
- Endodermal Sinus Tumor · Phase 3
- Endometrial Neoplasms · Phase 3
- Endothelium · Phase 2
- Enteral Nutrition · Phase 3
- Enteropathy-Associated T-Cell Lymphoma · Phase 2
- Ependymoma · Phase 3
- Epidermal Growth Factor · Phase 3
- Epstein-Barr Virus Infections · Phase 2/Phase 3
- Erb-b2 Receptor Tyrosine Kinases · Phase 3
- Esophageal Diseases · Phase 2
- Esophageal Neoplasms · Phase 4
- Esophageal Squamous Cell Carcinoma · Phase 4
- Esophagogastric Junction · Phase 2
- Esthesioneuroblastoma, Olfactory · Phase 2
- Exploratory Behavior · Phase 2
- Fallopian Tube Neoplasms · Phase 3
- Fatigue · Phase 2
- Fertility Preservation · Phase 2
- Gallbladder Neoplasms · Phase 3
- Ganglioneuroblastoma · Phase 3
- Gastrointestinal Neoplasms · Phase 2
- Gastrointestinal Stromal Tumors · Phase 2
- General Surgery · Phase 3
- Genes, erbB-1 · Phase 2
- Genes, erbB-2 · Phase 3
- Genes, ras · Phase 1/Phase 2
- Genital Neoplasms, Female · Phase 2
- Genital Neoplasms, Male · Phase 2
- Germinoma · Phase 3
- Gestational Trophoblastic Disease · Phase 3
- Giant Cell Tumors · Phase 2
- Glioblastoma · Phase 2/Phase 3
- Glioma · Phase 3
- Graft vs Host Disease · Phase 2
- Granulocyte-Macrophage Colony-Stimulating Factor · Phase 2
- Hamartoma · Phase 3
- Head and Neck Neoplasms · Phase 4
- Hearing Loss · Phase 2
- Hematopoietic Stem Cell Mobilization · Phase 3
- Hepatoblastoma · Phase 3
- Histone Deacetylase Inhibitors · Phase 2
- HIV Infections · Phase 2
- Hodgkin Disease · Phase 3
- Homologous Recombination · Phase 2/Phase 3
- Human papillomavirus 16 · Phase 2
- Hydatidiform Mole · Phase 3
- Hyperthermic Intraperitoneal Chemotherapy · Phase 2
- Hypopharyngeal Neoplasms · Phase 3
- Hypoxia · Phase 2
- Hysterectomy · Phase 2
- Immune Checkpoint Inhibitors · Phase 3
- Immune System Diseases · Phase 2
- Immunoglobulin Light-chain Amyloidosis · Phase 2
- Immunoglobulin Light Chains · Phase 2
- Immunoproliferative Disorders · Phase 2
- Immunotherapy · Phase 3
- Induction Chemotherapy · Phase 1
- Inflammatory Breast Neoplasms · Phase 3
- Intestinal Diseases · Phase 1/Phase 2
- Intestinal Neoplasms · Phase 2
- Kartagener Syndrome · Phase 2
- Kidney Failure, Chronic · Phase 1
- Kidney Neoplasms · Phase 2
- Klatskin Tumor · Phase 3
- Laparoscopy · Phase 2
- Laparotomy · Phase 2
- Lapatinib · Phase 2
- Laryngeal Neoplasms · Phase 3
- Leukemia · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Lip Neoplasms · Phase 2
- Liposarcoma · Early Phase 1
- Liver Cirrhosis · Phase 3
- Liver Diseases · Phase 2
- Liver Neoplasms · Phase 3
- Lung · Phase 2
- Lung Diseases · Phase 3
- Lung Neoplasms · Phase 4
- Lymphatic Diseases · Phase 2
- Lymphatic Metastasis · Phase 3
- Lymphocytes, Tumor-Infiltrating · Phase 2
- Lymphohistiocytosis, Hemophagocytic · Phase 4
- Lymphoid Tissue · Phase 2
- Lymphoma · Phase 3
- Lymphoma, AIDS-Related · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Anaplastic · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 4
- Lymphoma, Non-Hodgkin · Phase 3
- Lymphoma, T-Cell · Phase 4
- Lymphoma, T-Cell, Peripheral · Phase 4
- Lymphoproliferative Disorders · Phase 2
- Malaria · Phase 3
- Mediastinal Neoplasms · Phase 3
- Medical Oncology · Phase 1
- Medulloblastoma · Phase 3
- Melanoma · Phase 4
- Mesothelioma · Phase 3
- Mesothelioma, Malignant · Phase 3
- Methotrexate · Phase 3
- Minimally Invasive Surgical Procedures · Phase 2
- Mouth · Phase 3
- Mouth Neoplasms · Phase 3
- Mucositis · Phase 3
- Multiple Myeloma · Phase 3
- Mutation · Phase 3
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 1/Phase 2
- Nasal Cavity · Phase 2
- Nasopharyngeal Carcinoma · Phase 4
- Nasopharyngeal Diseases · Phase 3
- Nasopharyngeal Neoplasms · Phase 3
- Nausea · Phase 3
- Neoadjuvant Therapy · Phase 3
- Neoplasm Metastasis · Phase 3
- Neoplasm Recurrence, Local · Phase 3
- Neoplasms · Phase 4
- Neoplasms by Histologic Type · Phase 3
- Neoplasms by Site · Phase 3
- Neoplasms, Connective and Soft Tissue · Phase 2/Phase 3
- Neoplasms, Connective Tissue · Phase 2/Phase 3
- Neoplasms, Germ Cell and Embryonal · Phase 4
- Neoplasms, Glandular and Epithelial · Phase 1/Phase 2
- Neoplasms, Nerve Tissue · Phase 3
- Neoplasms, Squamous Cell · Phase 3
- Neoplasms, Unknown Primary · Phase 2
- Neuroblastoma · Phase 3
- Neuroectodermal Tumors · Phase 3
- Neuroectodermal Tumors, Primitive · Phase 2
- Neuroendocrine Tumors · Phase 4
- Neurotoxicity Syndromes · Phase 1
- Neutropenia · Phase 2
- Nutrition Therapy · Phase 3
- Oncogenes · Phase 1
- Oropharyngeal Neoplasms · Phase 4
- Oropharynx · Phase 2
- Osteosarcoma · Phase 3
- Ototoxicity · Phase 3
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 3
- Paclitaxel · Phase 1
- Paget Disease, Extramammary · Phase 2
- Pain · Phase 3
- Pancreatic Diseases · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 4
- Papillomaviridae · Phase 2
- Papillomavirus Infections · Phase 2
- Paranasal Sinuses · Phase 2
- Paranasal Sinus Neoplasms · Phase 3
- Pathology · Phase 2
- Patient Reported Outcome Measures · Phase 2
- Pediatrics · Phase 3
- Penile Neoplasms · Phase 2
- Perioperative Period · Phase 2
- Peritoneal Neoplasms · Phase 3
- Peritoneum · Phase 2
- Pharmacology · Phase 3
- Pharyngeal Diseases · Phase 1/Phase 2
- Pharyngeal Neoplasms · Phase 3
- Pheochromocytoma · Phase 2
- Pinealoma · Early Phase 1
- Plasmacytoma · Phase 2
- Pleura · Phase 2
- Pleural Effusion · Phase 1
- Pleural Effusion, Malignant · Phase 3
- Pleural Neoplasms · Phase 2
- Positron Emission Tomography Computed Tomography · Phase 2
- Precancerous Conditions · Phase 3
- Probiotics · Phase 2
- Progression-Free Survival · Phase 3
- Prostatic Neoplasms · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Prosthesis Failure · Phase 3
- Quality of Life · Phase 3
- Radiation · Phase 3
- Radiation Exposure · Phase 3
- Radiation Oncology · Phase 2
- Radiosurgery · Phase 2
- Radiotherapy · Phase 3
- Randomized Controlled Trial · Phase 2
- ras GTPase-Activating Proteins · Phase 1
- ras Proteins · Phase 2
- Receptors, Fibroblast Growth Factor · Phase 3
- Receptors, Tumor Necrosis Factor, Type I · Phase 2/Phase 3
- Rectal Neoplasms · Phase 2
- Recurrence · Phase 3
- Respiratory Tract Diseases · Phase 3
- Respiratory Tract Neoplasms · Phase 3
- Retinoblastoma · Phase 3
- Retroperitoneal Neoplasms · Phase 1
- Rhabdoid Tumor · Phase 3
- Rhabdomyosarcoma · Phase 2
- Rituximab · Phase 2
- Salivary Gland Neoplasms · Phase 3
- Sarcoma · Phase 3
- Sarcoma, Ewing · Phase 2
- Seminoma · Phase 3
- Sentinel Lymph Node · Phase 2
- Skin Neoplasms · Phase 3
- Small Cell Lung Carcinoma · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 4
- Stomach Diseases · Phase 1
- Stomach Neoplasms · Phase 3
- Stomatitis · Phase 3
- Survival · Phase 3
- Survival Rate · Early Phase 1
- Teratoma · Phase 3
- Testicular Neoplasms · Phase 3
- Therapeutics · Phase 2
- Thoracic Neoplasms · Phase 3
- Thrombocytopenia · Phase 2
- Thymidylate Synthase · Phase 2
- Thymoma · Phase 3
- Thyroid Carcinoma, Anaplastic · Phase 1/Phase 2
- Thyroid Neoplasms · Phase 2
- Tongue Neoplasms · Phase 3
- Triple Negative Breast Neoplasms · Phase 3
- Ureteral Neoplasms · Phase 3
- Urethral Neoplasms · Phase 3
- Urinary Bladder · Phase 2
- Urinary Bladder Neoplasms · Phase 3
- Urogenital Neoplasms · Phase 2
- Urologic Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 4
- Uterine Neoplasms · Phase 3
- Vaginal Neoplasms · Phase 2
- Vinblastine · Phase 3
- Vinorelbine · Phase 2
- Vulvar Neoplasms · Phase 3
- Waldenstrom Macroglobulinemia · Phase 2
- Wilms Tumor · Phase 1
- Xerostomia · Phase 2
- Yang Deficiency · Phase 2
- Yin Deficiency · Phase 2
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Approval history
- approvedDec 19, 1978
Chemistry & pharmacology
SMILES
N.N.[Cl-].[Cl-].[Pt++]- Mol. weight
- 300.051 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaCisplatin ↗
- NCATSQ20Q21Q62J ↗
- ChEMBLCHEMBL2068237 ↗
- ChEMBLCHEMBL1235478 ↗
- ChEMBLCHEMBL11359 ↗
Also known as
- cddp
- cddp
- ciplatin
- cis-ddp
- cis-ddp
- cis-diamminedichloroplatinum(ii)
- cis-diamminedichloroplatinum(ii)
- cisplatin
- cisplatin
- cisplatin
- cisplatin
- cisplatin
- cisplatin
- cisplatin
- cisplatin
- cisplatin
- cisplatin
- cisplatin liposomal
- cisplatinum
- cisplatinum
- cis-platinum
- cis-platinum
- cis-platinum
- cis-platinum ii
- cis-platinum ii
- liposomal cisplatin
- nc6004
- nc 6004
- nc-6004
- nc-6004
- nov-002
- nov-002
- platine
- platine
- platinol
- platinol
- platinol
- platinol
- platinum
- platinum
- platinum
- platinum
- platinum diamminodichloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281417 | Phase 2 | Feb 27, 2026 | National Cancer Institute (NCI), Ohio State University |
| NCT07218913 | Phase 1 | Feb 4, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07279935 | Phase 4 | Jan 15, 2026 | AstraZeneca |
| NCT07276360 | Phase 2 | Jan 3, 2026 | National Institutes of Health (NIH), Uganda Cancer Institute, Varian Medical Systems |
| NCT07295262 | Early Phase 1 (Phase 1) | Jan 1, 2026 | Sichuan University |
| NCT07141771 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Chinese Academy of Medical Sciences |
| NCT07221253 | Phase 3 | Dec 31, 2025 | AstraZeneca |
| NCT07263919 | Phase 2 | Dec 31, 2025 | Akeso Pharmaceuticals, Inc., People's Liberation Army of China |
| NCT07268040 | Phase 2 | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07283991 | Phase 2 | Dec 30, 2025 | Jiao Tong University |
| NCT06724042 | Phase 1 | Dec 30, 2025 | InSilico Medicine Hong Kong Limited |
| NCT07310784 | Phase 2 | Dec 16, 2025 | Government of China |
| NCT07139951 | Phase 2 | Dec 11, 2025 | Mayo Clinic |
| NCT07219212 | Phase 1 | Dec 11, 2025 | Johnson and Johnson |
| NCT07276399 | Phase 3 | Dec 3, 2025 | — |
| NCT07214779 | Phase 3 | Dec 1, 2025 | ENGOT Foundation, GOG Foundation, Inc., Incyte |
| NCT07238569 | Phase 3 | Dec 1, 2025 | Sun Yat-Sen University |
| NCT07244965 | Phase 2 | Dec 1, 2025 | Zhejiang University |
| NCT07078604 | Phase 2 | Dec 1, 2025 | Kuni Foundation, University of Washington |
| NCT07229625 | Phase 3 | Nov 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Organizations
Research & Development (1,240)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 565 | 196 | 4 | 1990 |
| Sun Yat-Sen University | Academic/Hospital | 190 | 159 | 5 | 1998 |
| Merck | For profit | 117 | 62 | 3 | 2005 |
| Fudan University | Academic/Hospital | 113 | 90 | 4 | 2006 |
| AstraZeneca | For profit | 108 | 59 | 5 | 2000 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 106 | 68 | 5 | 2002 |
| Eli Lilly | For profit | 99 | 79 | 4 | 2000 |
| Cornell University | Academic/Hospital | 93 | 74 | 4 | 1994 |
| University of Texas at Houston | Academic/Hospital | 89 | 62 | 4 | 1992 |
| Harvard University | Academic/Hospital | 76 | 49 | 4 | 1994 |
| Jiao Tong University | Academic/Hospital | 72 | 55 | 5 | 1997 |
| Roche | For profit | 67 | 42 | 4 | 2001 |
| Bristol-Myers Squibb | For profit | 65 | 28 | 3 | 2002 |
| Sanofi | For profit | 62 | 31 | 5 | 1997 |
| Peking University | Academic/Hospital | 61 | 37 | 5 | 2005 |
| People's Liberation Army of China | Government | 59 | 32 | 4 | 2008 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 58 | 49 | 3 | 1993 |
| Gynecologic Oncology Group | Academic/Hospital | 51 | 45 | 4 | 1992 |
| NRG Oncology | Academic/Hospital | 51 | 8 | 4 | 1994 |
| Southwest Oncology Group | Academic/Hospital | 51 | 28 | 4 | 1992 |
Marketing (14)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Aug 18, 2015 |
| Bedford Pharmaceuticals | For profit | MKTG | Nov 14, 2000 |
| Bristol-Myers | For profit | NDA | Dec 19, 1978 |
| Fresenius | For profit | MKTG | Jul 16, 1999 |
| Gland Pharma Ltd | For profit | MKTG | Mar 17, 2017 |
| Gland Pharma Ltd | For profit | SYN | Mar 17, 2017 |
| Hikma | For profit | MKTG | Nov 7, 2000 |
| Hq Speciality Pharma | For profit | NDA2 | Dec 19, 1978 |
| Mylan | For profit | MKTG | Apr 18, 2012 |
| PHARMOBEDIENT | For profit | MKTG | Apr 18, 2012 |
| Pharmachemie Bv | For profit | MKTG | May 16, 2000 |
| Qilu Pharmaceutical Co., Ltd. | For profit | MKTG | May 10, 2024 |
| Teva | For profit | MKTG | May 16, 2000 |
| West-Ward Pharmaceutical | For profit | MKTG | Nov 7, 2000 |